Compare AbbVie Inc (ABBV) vs Vanguard Intermediate Term Corporate Bond ETF (VCIT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Vanguard Intermediate Term Corporate Bond ETF — how do they compare? AbbVie Inc trades at $252.67 (market cap $449.91B), while Vanguard Intermediate Term Corporate Bond ETF trades at $81.81. The key difference: AbbVie Inc pays a 2.72% dividend while Vanguard Intermediate Term Corporate Bond ETF pays none, and AbbVie Inc is trading nearer its 52-week high, Vanguard Intermediate Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| ABBV | VCIT | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | Fixed Income |
52-Week High | $261.07 | $84.82 |
52-Week Low | $184.85 | $81.54 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.61, down 0.84% on the day, with a bullish technical outlook supported by moving averages and strong support at $248. The company reported revenue of $61.16B in 2025, with EPS beats in recent quarters, though net income margin has trended down to 5.79%. Key growth drivers Skyrizi and Rinvoq are offsetting Humira declines, with positive clinical updates like the Phase 2 ELAHERE data at SGO 2026.
The stock offers a compelling buy case with a consensus price target of $266.33 (5.4% upside) and strong analyst support (68% buy ratings). However, risks include patent cliffs in the 2030s, high debt levels, and margin pressure. Dividend growth is recovering, supporting income investors, but execution on pipeline assets remains critical for sustained expansion.
VCIT trades at $82.39 with minimal daily movement (+0.06%) amid bearish technical signals from moving averages. The ETF maintains a competitive 0.03% expense ratio and approximately 5.17% SEC yield, positioning it as a cost-effective intermediate-term corporate bond option. Recent dividend distributions of $0.33-$0.34 highlight consistent income generation, though technical indicators show 14 sell signals against 2 buy signals.
Outlook remains cautious due to bearish technical momentum and corporate bond market sensitivity to interest rate changes. The fund's low-cost structure and steady yield appeal to income-focused investors, but potential volatility from Federal Reserve policy shifts presents near-term risk. Current levels near support at $82 require monitoring for breakdown confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Vanguard Intermediate Term Corporate Bond ETF
VCIT tracks the Bloomberg U.S. 5-10 Year Corporate Bond Index, providing exposure to investment-grade debt from industrial, utility, and financial companies. It acts as a middle-ground bond fund, offering higher yields than short-term bonds with less price volatility than long-term corporate debt.
Read more on VCIT →
